Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Royal Bank of Canada reduced their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Down 0.2 %

NASDAQ:MRNS opened at $0.55 on Friday. The company has a fifty day moving average of $0.49 and a 200 day moving average of $0.85. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $10.50. The firm has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MRNS. Assenagon Asset Management S.A. grew its position in shares of Marinus Pharmaceuticals by 70.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after buying an additional 183,396 shares during the period. abrdn plc grew its position in shares of Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares during the period. GSA Capital Partners LLP grew its position in shares of Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 817,050 shares during the period. Suvretta Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the period. 98.80% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.